<SEC-DOCUMENT>0000899243-23-000828.txt : 20230105
<SEC-HEADER>0000899243-23-000828.hdr.sgml : 20230105
<ACCEPTANCE-DATETIME>20230105063022
ACCESSION NUMBER:		0000899243-23-000828
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20230101
FILED AS OF DATE:		20230105
DATE AS OF CHANGE:		20230105

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Badawi David
		CENTRAL INDEX KEY:			0001870825

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40587
		FILM NUMBER:		23509683

	MAIL ADDRESS:	
		STREET 1:		C/O SIGHT SCIENCES, INC.
		STREET 2:		4040 CAMPBELL AVENUE, SUITE 100
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sight Sciences, Inc.
		CENTRAL INDEX KEY:			0001531177
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				800625749
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		3000 SAND HILL ROAD
		STREET 2:		BUILDING 3, SUITE 105
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		(415) 889-0550

	MAIL ADDRESS:	
		STREET 1:		3000 SAND HILL ROAD
		STREET 2:		BUILDING 3, SUITE 105
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>doc4.xml
<DESCRIPTION>FORM 4 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2023-01-01</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001531177</issuerCik>
        <issuerName>Sight Sciences, Inc.</issuerName>
        <issuerTradingSymbol>SGHT</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001870825</rptOwnerCik>
            <rptOwnerName>Badawi David</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O SIGHT SCIENCES, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>4040 CAMPBELL AVE., SUITE 100</rptOwnerStreet2>
            <rptOwnerCity>MENLO PARK</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>94025</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Technology Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2023-01-01</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>28100</value>
                    <footnoteId id="F1"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.00</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>1488221</value>
                    <footnoteId id="F2"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2023-01-04</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>F</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>2431</value>
                    <footnoteId id="F3"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>12.21</value>
                    <footnoteId id="F4"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>1485790</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">Reflects a grant of restricted stock units (&quot;RSUs&quot;) made to the Reporting Person on February 9, 2022 under the Issuer's 2021 Incentive Award Plan (such grant, the &quot;RSU Grant&quot;), as reported in Table II on the Reporting Person's Form 4 filed with the Securities and Exchange Commission on February 11, 2022. Of the RSUs awarded to the Reporting Person under the 2022 RSU Grant, 25% vested on January 1, 2023, and an additional 25% vest on each of January 1, 2024, 2025, and 2026. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share (&quot;Common Stock&quot;). The RSUs have no expiration date.</footnote>
        <footnote id="F2">Includes 7,025 shares of Common Stock issued in connection with the January 1, 2023 vesting of the 2022 RSU Grant.</footnote>
        <footnote id="F3">Reflects shares of Common Stock withheld by the Issuer to cover the Reporting Person's tax liability in connection with the vesting of RSUs.</footnote>
        <footnote id="F4">Reflects the closing sale price of the Issuer's Common Stock as reported on The Nasdaq Global Select Market on December 30, 2022.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ Jeremy Hayden, Attorney-in-Fact for David Badawi</signatureName>
        <signatureDate>2023-01-04</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
